WX-081
Phase 2Small molecule
WX-081 is one of 33 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
129 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Mycobutin
PfizerPhase 3
Sirturo
WWim Janssens
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Galzin
AAmerican Regent, Inc.
Phase 3
Avelox
BayerPhase 2
Nicotine Free Cigarettes
PfizerPhase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 2
Zyvox
PfizerPhase 2
L-Arginine
Mario Negri Institute for Pharmacological ResearchPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WX-081. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details